Zvereff V, Wang J-C, Shun K, Lacoste J, Chevrette M
Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada.
Br J Cancer. 2007 Oct 8;97(7):941-8. doi: 10.1038/sj.bjc.6603964. Epub 2007 Sep 11.
CD9, a member of the tetraspanin family of proteins, is involved in a variety of cellular interactions with many other proteins and molecules. Although CD9 has been implicated in cell fusion, migration and cancer progression, the detailed function of this protein is not completely understood and likely depends on interactions with different protein partners, which are not yet all known. Using co-immunoprecipitation and mass-spectrometric protein sequencing, we have identified in prostate cancer cells, a novel CD9 partner, the 75-kDa protein HSPA9B, also known as mortalin. We further show that introduction and overexpression of wild-type CD9 into human PC-3 prostate cancer cells induces mitotic catastrophe. We also demonstrate, by immunocolocalisation studies, the interaction of CD9 and mortalin in PC-3 cells undergoing mitotic catastrophe. Our results not only identified mortalin as a new CD9 partner, but also clarify the mechanisms by which CD9 may control prostate cancer progression.
CD9是四跨膜蛋白家族的成员之一,参与多种细胞与许多其他蛋白质和分子的相互作用。尽管CD9与细胞融合、迁移和癌症进展有关,但其详细功能尚未完全明确,可能取决于与不同蛋白质伴侣的相互作用,而这些伴侣尚未完全知晓。通过免疫共沉淀和质谱蛋白质测序,我们在前列腺癌细胞中鉴定出一种新的CD9伴侣,即75 kDa蛋白HSPA9B,也称为mortalin。我们进一步表明,将野生型CD9导入并在人PC-3前列腺癌细胞中过表达会诱导有丝分裂灾难。我们还通过免疫共定位研究证明,在经历有丝分裂灾难的PC-3细胞中,CD9与mortalin相互作用。我们的研究结果不仅确定mortalin是一种新的CD9伴侣,还阐明了CD9可能控制前列腺癌进展的机制。